Scholarlink

Purpose <p>Immunotherapy has redefined the therapeutic landscape in extensive-stage small cell lung cancer (ES-SCLC). Whether the prophylactic cranial irradiation (PCI) remains relevant when paired with immunotherapy-based regimens remains unresolved. This study evaluated the efficacy of PCI in ES-SCLC patients treated with chemo-immunotherapy.</p> Materials and methods <p>A systematic review and pairwise meta-analysis were conducted per PRISMA guidelines, including studies from PubMed and Embase up to October 1, 2025. Outcomes were reported as hazard ratios (HR) for overall survival (OS), progression-free survival (PFS), brain metastasis-free survival (BMFS), and cumulative incidence of 1-year BM.</p> Results <p>Four retrospective cohort studies, with one only in form of abstract, involving 9992 participants were included. PCI combined with chemo-immunotherapy (<i>n</i> = 606) was associated with improved OS (HR = 0.78, 95%CI 0.68–0.9, p &lt; 0.001), PFS (HR = 0.73, 95%CI 0.63–0.85, p &lt; 0.001), and BMFS (HR = 0.36, 95%CI 0.24–0.54, <i>p</i> &lt; 0.001). The 1-year cumulative incidence of BM was 15.85% (95%CI: 10.87–20.83%) with PCI, and 44.11% (95%CI: 42.2–46.03%) without. A survival benefit was not observed in studies that included patients with baseline brain magnetic resonance imaging (MRI) (HR = 0.74, 95%CI 0.5–1.11, <i>p</i> = 0.137).</p> Conclusions <p>In this study PCI was associated with reduced BM incidence and improved prognosis. However, the apparent survival benefit was driven by large registry-based studies that did not report baseline brain MRI and was not observed in the subgroup of patients with confirmed negative baseline brain MRI. Given the nonrandomized evidence base, these findings should be interpreted with caution, and prospective randomized studies are needed to clarify whether the observed PCI benefit is prophylactic or therapeutic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prophylactic cranial irradiation in the era of immunotherapy in extensive-stage small cell lung cancer: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Dominik Wróbel,
  • Patryk Rogaczewski,
  • Natalia Ostruszka,
  • Jędrzej Borowczak,
  • Artur Bandura,
  • Paweł Michał Potocki

摘要

Purpose

Immunotherapy has redefined the therapeutic landscape in extensive-stage small cell lung cancer (ES-SCLC). Whether the prophylactic cranial irradiation (PCI) remains relevant when paired with immunotherapy-based regimens remains unresolved. This study evaluated the efficacy of PCI in ES-SCLC patients treated with chemo-immunotherapy.

Materials and methods

A systematic review and pairwise meta-analysis were conducted per PRISMA guidelines, including studies from PubMed and Embase up to October 1, 2025. Outcomes were reported as hazard ratios (HR) for overall survival (OS), progression-free survival (PFS), brain metastasis-free survival (BMFS), and cumulative incidence of 1-year BM.

Results

Four retrospective cohort studies, with one only in form of abstract, involving 9992 participants were included. PCI combined with chemo-immunotherapy (n = 606) was associated with improved OS (HR = 0.78, 95%CI 0.68–0.9, p < 0.001), PFS (HR = 0.73, 95%CI 0.63–0.85, p < 0.001), and BMFS (HR = 0.36, 95%CI 0.24–0.54, p < 0.001). The 1-year cumulative incidence of BM was 15.85% (95%CI: 10.87–20.83%) with PCI, and 44.11% (95%CI: 42.2–46.03%) without. A survival benefit was not observed in studies that included patients with baseline brain magnetic resonance imaging (MRI) (HR = 0.74, 95%CI 0.5–1.11, p = 0.137).

Conclusions

In this study PCI was associated with reduced BM incidence and improved prognosis. However, the apparent survival benefit was driven by large registry-based studies that did not report baseline brain MRI and was not observed in the subgroup of patients with confirmed negative baseline brain MRI. Given the nonrandomized evidence base, these findings should be interpreted with caution, and prospective randomized studies are needed to clarify whether the observed PCI benefit is prophylactic or therapeutic.